423 related articles for article (PubMed ID: 29617666)
1. Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Jayasinghe RG; Cao S; Gao Q; Wendl MC; Vo NS; Reynolds SM; Zhao Y; Climente-González H; Chai S; Wang F; Varghese R; Huang M; Liang WW; Wyczalkowski MA; Sengupta S; Li Z; Payne SH; Fenyö D; Miner JH; Walter MJ; ; Vincent B; Eyras E; Chen K; Shmulevich I; Chen F; Ding L
Cell Rep; 2018 Apr; 23(1):270-281.e3. PubMed ID: 29617666
[TBL] [Abstract][Full Text] [Related]
2. Discovery of driver non-coding splice-site-creating mutations in cancer.
Cao S; Zhou DC; Oh C; Jayasinghe RG; Zhao Y; Yoon CJ; Wyczalkowski MA; Bailey MH; Tsou T; Gao Q; Malone A; Reynolds S; Shmulevich I; Wendl MC; Chen F; Ding L
Nat Commun; 2020 Nov; 11(1):5573. PubMed ID: 33149122
[TBL] [Abstract][Full Text] [Related]
3. Detection of somatic TP53 splice site mutations in diffuse astrocytomas.
Uno M; Oba-Shinjo SM; de Aguiar PH; Leite CC; Rosemberg S; Miura FK; Junior RM; Scaff M; Nagahashi Marie SK
Cancer Lett; 2005 Jun; 224(2):321-7. PubMed ID: 15914282
[TBL] [Abstract][Full Text] [Related]
4. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
5. BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line.
Morrison A; Chekaluk Y; Bacares R; Ladanyi M; Zhang L
PLoS One; 2015; 10(4):e0119224. PubMed ID: 25830670
[TBL] [Abstract][Full Text] [Related]
6. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
7. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
8. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Yang Y; Swaminathan S; Martin BK; Sharan SK
Hum Mol Genet; 2003 Sep; 12(17):2121-31. PubMed ID: 12915465
[TBL] [Abstract][Full Text] [Related]
9. Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
Brose MS; Volpe P; Paul K; Stopfer JE; Colligon TA; Calzone KA; Weber BL
Genet Test; 2004; 8(2):133-8. PubMed ID: 15345110
[TBL] [Abstract][Full Text] [Related]
10. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
11. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
Sharp A; Pichert G; Lucassen A; Eccles D
Hum Mutat; 2004 Sep; 24(3):272. PubMed ID: 15300854
[TBL] [Abstract][Full Text] [Related]
12. Systematic discovery of complex insertions and deletions in human cancers.
Ye K; Wang J; Jayasinghe R; Lameijer EW; McMichael JF; Ning J; McLellan MD; Xie M; Cao S; Yellapantula V; Huang KL; Scott A; Foltz S; Niu B; Johnson KJ; Moed M; Slagboom PE; Chen F; Wendl MC; Ding L
Nat Med; 2016 Jan; 22(1):97-104. PubMed ID: 26657142
[TBL] [Abstract][Full Text] [Related]
13. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
[TBL] [Abstract][Full Text] [Related]
14. Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.
Krivokuca A; Dragos VS; Stamatovic L; Blatnik A; Boljevic I; Stegel V; Rakobradovic J; Skerl P; Jovandic S; Krajc M; Magic MB; Novakovic S
Fam Cancer; 2018 Apr; 17(2):179-185. PubMed ID: 28685474
[TBL] [Abstract][Full Text] [Related]
15. UG repeats/TDP-43 interactions near 5' splice sites exert unpredictable effects on splicing modulation.
Passoni M; De Conti L; Baralle M; Buratti E
J Mol Biol; 2012 Jan; 415(1):46-60. PubMed ID: 22100394
[TBL] [Abstract][Full Text] [Related]
16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Zhang M; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Feb; 132(1):335-40. PubMed ID: 22116506
[TBL] [Abstract][Full Text] [Related]
18. K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay.
Lee SY; Park JH; Jeong S; Kim BY; Kang YK; Xu Y; Chung SK
Oncogene; 2019 Mar; 38(10):1597-1610. PubMed ID: 30348990
[TBL] [Abstract][Full Text] [Related]
19. A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
Li D; Bi FF; Chen NN; Cao JM; Sun WP; Zhou YM; Li CY; Yang Q
Cell Cycle; 2014; 13(21):3442-9. PubMed ID: 25485588
[TBL] [Abstract][Full Text] [Related]
20. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
